Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 6/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21603395 | 0.87 | HPGD (0.36) | MEN1KMT2AHPGDNPSR1MAPT | |
| SCHEMBL17659048 | 0.85 | NQO2 (0.34) | MEN1KMT2AMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL24778598 | 0.81 | HPGD (0.40) | MEN1KMT2AHPGDNPSR1MAPT | |
| SCHEMBL19225447 | 0.78 | MAPT (0.33) | MEN1KMT2AHPGDNPSR1MAPT | |
| SCHEMBL30329719 | 0.78 | MAPT (0.40) | MEN1KMT2AHPGDNPSR1MAPT | |
| SCHEMBL21603522 | 0.77 | GRIA2 (0.37) | MEN1KMT2AHPGDNPSR1MAPT | |
| SCHEMBL29284941 | 0.76 | PARP1 (0.36) | — | |
| SCHEMBL23013231 | 0.76 | HTR2A (0.31) | — | |
| SCHEMBL29362737 | 0.76 | ALDH1A1 (0.47) | MEN1KMT2AHPGDMAPTKDM4E | |
| SCHEMBL3344312 | 0.76 | ALDH1A1 (0.47) | MEN1KMT2AHPGDMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108558842-B | Pyrimidine derivative anaplastic lymphoma kinase inhibitor | 山东轩竹医药科技有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-107108586-B | Polycyclic anaplastic lymphoma kinase inhibitors | 山东轩竹医药科技有限公司 | 2020-07-10 | — | — | CN | disclosed |
| CN-106146478-B | Triazine derivatives species anaplastic lymphoma kinase inhibitor | 海南轩竹医药科技有限公司 | 2019-07-16 | — | — | CN | disclosed |
| US-10011592-B2 | Polycyclic inhibitor of anaplastic lymphoma kinase | Xuanzhu Pharma Co., Ltd. (CN) | 2018-07-03 | — | — | US | disclosed |
| US-10011592-B2 | Polycyclic inhibitor of anaplastic lymphoma kinase | Xuanzhu Pharma Co., Ltd. (CN) | 2018-07-03 | — | — | US | disclosed |
| US-20180086745-A9 | POLYCYCLIC INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2018-03-29 | — | — | US | disclosed |
| US-20180086745-A9 | POLYCYCLIC INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE | Xuanzhu Biopharmaceutical Co., Ltd. (CN) | 2018-03-29 | — | — | US | disclosed |
| US-20170240534-A1 | POLYCYCLIC INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE | XUANZHU PHARMA CO LTD (CN) | 2017-08-24 | — | — | US | disclosed |
| US-20170240534-A1 | POLYCYCLIC INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE | XUANZHU PHARMA CO LTD (CN) | 2017-08-24 | — | — | US | disclosed |
| EP-3202765-A1 | POLYCYCLIC ANAPLASTIC LYMPHOMA KINASE INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016050171-A1 | POLYCYCLIC ANAPLASTIC LYMPHOMA KINASE INHIBITOR | 山东轩竹医药科技有限公司 | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086745-A9 | POLYCYCLIC INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE | IKBKE, DCK, CHUK | MEN1 1808/4885KMT2A 685/4885HPGD 2824/4885 |
| US-10011592-B2 | Polycyclic inhibitor of anaplastic lymphoma kinase | IKBKE, DCK, CHUK | MEN1 1808/4885KMT2A 685/4885HPGD 2824/4885 |
| US-20170240534-A1 | POLYCYCLIC INHIBITOR OF ANAPLASTIC LYMPHOMA KINASE | IKBKE, DCK, CHUK | MEN1 1808/4885KMT2A 685/4885HPGD 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.